Overcoming molecular mechanisms of resistance to therapies for non-small cell lung cancer
Results of ASCEND-4 trial of ceritinib versus chemotherapy in ALK+ NSCLC patients
Gilberto De Castro Jr
Immuno-oncology agents plus tyrosine kinase inhibitors?
CheckMate 153 trial: how long should nivolumab be taken for?
Maximizing treatment benefits in NSCLC